moneyheap
HLN · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Haleon plc American Depositary Shares (Each representing two Ordinary Shares) (HLN) stock moving?
Haleon's shares fell about 14% on Oct 29, from a 10.00 close to 8.57 on 56.8M volume, after the company cut its FY26 organic revenue growth outlook to about 2.5% from 3% to 5%. The cut was tied to weaker respiratory sales, a China Centrum OTC classification issue that management does not expect to resolve in 2027, and Brazil go-to-market changes; the CEO noted that season start had not yet been seen in international markets. Sell-side sentiment then moved toward Hold: Deutsche Bank upgraded from Sell to Hold with a 310p target, while Berenberg and Jefferies downgraded to Hold and Goldman Sachs dropped the stock from its European Conviction List. Supporting the shares, Haleon launched a £500M buyback on Oct 29 and disclosed purchases of 12.57M shares in early November at roughly 316p to 344p, and a non-executive director bought 7,670 shares at £3.242. Since the Nov 3 to Nov 5 peak area, the stock has eased, closing at 9.06 on Nov 10 after a rebound from the 8.57 low, which is still about 9% below the pre-guidance close. Volume has normalised to 14M to 17M shares a day from the post-announcement spike. The balance of evidence is mixed: the buyback and insider purchase offer support, while the guidance cut, the downgrades and the unresolved China and respiratory-season questions weigh on the outlook.
News behind the analysis
- Haleon plc Announces Share Buyback TransactionHaleon bought 12,572,956 of its own ordinary shares to hold as treasury shares under its existing buyback program.
- Jefferies Downgrades Haleon to Hold from BuyJefferies cut Haleon from Buy to Hold, reflecting a change in its outlook on the company.
- Goldman Sachs Removes Haleon from European Conviction ListGoldman Sachs removed Haleon from its European Conviction List as part of a broader portfolio adjustment.
- Berenberg Downgrades Haleon to HoldBerenberg lowered its rating on Haleon to Hold and reduced its price target for the shares.
- Haleon plc Announces PDMR Transaction NotificationHaleon disclosed a share purchase by Independent Non-Executive Director Bláthnaid Bergin, 7,670 shares at £3.242.
- Deutsche Bank Upgrades Haleon to Hold and Adjusts Price TargetDeutsche Bank upgraded Haleon from Sell to Hold and lowered its price target to 310p from 320p.
- Haleon Cuts Full-Year Organic Revenue Growth GuidanceHaleon lowered its full-year organic revenue growth outlook to about 2.5% from 3% to 5%, citing weaker respiratory health sales.
- Haleon Adjusts FY26 Organic Revenue Growth To ~2.5%, High-Single-Digit Adjusted Operating Profit Growth At Constant Currency, Net Interest Of ~£255 Million, Incorporating China Centrum OTC Product Classification Changes And Accelerated Brazil Go-To-Market Model RolloutHaleon set FY26 organic revenue growth at about 2.5% and kept high-single-digit adjusted operating profit growth at constant currency, citing China Centrum OTC classification changes and a Brazil go-to-market rollout.
- Consumer Healthcare Giant Haleon Plunges to 52-Week LowHaleon shares hit a 52-week low after the company trimmed full-year sales targets amid China import halts and Brazil adjustments.
- Haleon plc Commences £500 Million Share Buyback ProgrammeHaleon launched a buyback of up to £500 million to reduce share capital and fulfil employee share plan obligations.
About Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
Haleon is a UK-based consumer health company that GSK spun off in 2022. It sells everyday health brands such as Sensodyne, parodontax, Advil, Panadol, Centrum, Voltaren, Theraflu and Tums, and its shares trade in London and in New York, where each US share (ADR) represents two ordinary shares.
How it makes money
It sells branded over-the-counter health and oral-care products through pharmacies, supermarkets, e-commerce and hospital channels. Revenue is roughly £11bn a year (about £5.6bn in the first half of 2026). It comes from six categories: oral health (the largest, led by Sensodyne), vitamins and supplements, pain relief, respiratory health, digestive health, and skin health. In H1 2026, developed markets brought in about 63% of revenue. Emerging markets such as India and China grew faster. Gross margins are high, around 66%, and the company spends about a fifth of revenue on advertising and promotion.
What usually moves HLN
- Organic sales growth and pricing versus volume
- Strength of cold and flu seasons
- Gross margin expansion from productivity programmes
- Currency moves (it reports in pounds; FX swings affect results)
- Emerging-market growth, especially India and China